AzTrials
AzTrials

Chronic Stroke SurvivorsNCT06470009

Portable Neuromodulation Stimulator (PoNS®) Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Randomized Controlled Trial.

A study testing Portable Neuromodulation Stimulator (PoNS) in people with Chronic Stroke Survivors, run by Helius Medical Inc at 3 sites in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Double blind, randomized, placebo controlled, interventional clinical trial investigating the efficacy and safety of PoNS therapy on improving dynamic gait and balance deficits in chronic stroke survivors. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Chronic Stroke Survivors
What is being tested?
Portable Neuromodulation Stimulator (PoNS)
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
3 sitesCanada
Study dates
12 Jun 2024to 30 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women ≥ 18 and < 85 years of age with a diagnosis ischemic or hemorrhagic stroke at > 6 months since stroke onset event.
  • FMA-LE scores < 34 at screening with residual paresis in the lower extremity.
  • Able to walk at least 10 feet with or without assistive device.
  • FGA score < 23 at screening.
  • Montreal Cognitive Assessment 5-min (MoCA 5-min) ≥ 6
  • Able to understand, learn and apply instructions on how to operate the PoNS device and perform the rehabilitation exercise program.

Who cannot join

  • Pre-existing neurological disorders or previous stroke affecting the other hemisphere.
  • Severe arthritis or orthopedic problems that limit passive range of motion.
  • Areas of recent bleeding or open wounds; or areas that lack normal sensation on the tongue.
  • Diagnosis of dementia or mild cognitive impairment
  • Concurrent daily use of transcutaneous electric nerve stimulation (TENS) and/or other peripheral stimulation devices (i.e. Bioness®)
  • Neurostimulation therapy over the previous 6 months
Show all 12Show fewer
  • Cancer treatment within the past year.
  • Nonremovable metal orthodontic devices.
  • Oral health problems.
  • Chronic infectious diseases.
  • Pregnancy.
  • Sensitivity to nickel, gold or copper.

Trial locations and contacts

3 sites in 1 country.

Canada3 sites
  • Synaptic Health

    Calgary, Alberta, T2G 3A5

  • Neuphysio

    London, Ontario, N6J 2K4

  • Neuro-Concept

    Verdun, Quebec, H4H1M5

Other trials in Canada

About this study

Double blind, randomized, placebo controlled, interventional clinical trial investigating the efficacy and safety of PoNS therapy on improving dynamic gait and balance deficits in chronic stroke survivors.

Read the detailed description

Double blind, randomized, placebo controlled, interventional clinical trial investigating the efficacy and safety of PoNS therapy on improving dynamic gait and balance deficits in chronic stroke survivors.

The Study Intervention Therapy is a therapeutic rehabilitation program that uses the PoNS device, Active or Sham, in conjunction with individualized physical exercise regimen.

The data from this prospective, double-arm, multi-site study that will enroll 40 subjects at 2-3 different clinical sites will be used to augment efficacy and safety data obtained in the RCT (which will randomize 60 subjects 1:1 into either active PoNS combined with DGB training versus DGB training with a sham device) and the OLS (which will enroll 30 subject into one active treatment arm). The totality of the proposed clinical evidence spans 3-4 sites and approximately 120 participants.

Eligible study participants will be randomized to either active PoNS ["Study Intervention"] device ["active"] or placebo PoNS ["Study Intervention"] device ["sham"]. Participants will work with a study physical therapist - trained in PoNS Therapy by HMI Medical and registered as a PoNS Trainer (Trainer).

The Trainer will prepare a DGB training exercise program appropriate to the participant's ability level and instruct on how to perform the breathing and awareness (mindfulness) training (BAT). To ensure patient's safety during rehabilitation at home, the Trainer may assign a DGB training program slightly different from the one performed in clinic.

All participants will undergo a total of twelve weeks of DGB training program combined with active or sham device's study treatment, performed both in clinic (4 weeks, Part 1), supervised by the Trainer, and at home (8 weeks, Part 2), mostly unsupervised. At the end of the treatment period, they will be asked to return to the clinic site for the follow-up visit 12 weeks after the end of the treatment period, as shown below:

Participants will receive individualized balance and gait rehabilitation protocols appropriate to their ability level and breathing and awareness (mindfulness) training. (Table 1) During the training sessions in clinic and, subsequently, during at-home training period, the trainer can adjust /flex the DGB training based on the participant's individual response to the Study Intervention Therapy (Table 1). During Part 2, the Trainer will follow-up weekly with participants in the clinic.

Table 1

Twelve weeks after completing the 12-week treatment phase of the study, participants will be required to return to the clinic for the final assessment of treatment effect. During the 12-week follow-up period (Part 3), participants will no longer utilize the Study Intervention device but will still be encouraged to continue with their physical rehabilitation program for the duration follow-up period until the final study visit.

Being tested
Portable Neuromodulation Stimulator (PoNS)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Portable Neuromodulation Stimulator (PoNS)Device

    Also called PoNS Therapy

    The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.

  • Portable Neuromodulation Stimulator (PoNS)Device

    Also called PoNS Therapy

    The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.

Study groups in NCT06470009
Study groupRoleWhat they receive
Arm 1Sham comparatoradministration of translingual neurostimulation.
Receives: Device: Portable Neuromodulation Stimulator (PoNS)
Arm 2Active comparatoradministration of translingual neurostimulation.
Receives: Device: Portable Neuromodulation Stimulator (PoNS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary safety endpoints

    treatment - related serious adverse events (SAE) over 12 week treatment

    Measured: 12 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2024
  2. Study start12 Jun 2024
  3. Primary completion30 Jul 2025
  4. Study completion30 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06470009
Sponsor's protocol ID
HMI-SA-PoNS-STK002
Status last verified
Sep 2025
First submitted
17 Jun 2024
Last updated
8 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Portable Neuromodulation Stimulator (PoNS) in people with Chronic Stroke Survivors, run by Helius Medical Inc at 3 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary safety endpoints (time frame: 12 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in